March 2 (Reuters) - Orchard Therapeutics PLC :
* ORCHARD THERAPEUTICS REPORTS 2020 FINANCIAL RESULTS AND REVIEWS RECENT ACCOMPLISHMENTS
* ORCHARD THERAPEUTICS PLC - $150 MILLION STRATEGIC FINANCING SUPPORTS EXECUTION INTO FIRST HALF OF 2023
* ORCHARD THERAPEUTICS PLC - OTL-200 U.S. FILING STRATEGY FOR METACHROMATIC LEUKODYSTROPHY (MLD) EXPECTED BY MID-2021
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
* ORCHARD THERAPEUTICS REPORTS 2020 FINANCIAL RESULTS AND REVIEWS RECENT ACCOMPLISHMENTS
* ORCHARD THERAPEUTICS PLC - $150 MILLION STRATEGIC FINANCING SUPPORTS EXECUTION INTO FIRST HALF OF 2023
* ORCHARD THERAPEUTICS PLC - OTL-200 U.S. FILING STRATEGY FOR METACHROMATIC LEUKODYSTROPHY (MLD) EXPECTED BY MID-2021
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)